日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

Talazoparib versus chemotherapy in patients with germline BRCA1/2-mutated HER2-negative advanced breast cancer: final overall survival results from the EMBRACA trial

在携带胚系 BRCA1/2 突变、HER2 阴性的晚期乳腺癌患者中,他拉唑帕尼与化疗的疗效比较:EMBRACA 试验的最终总生存期结果

Litton, J K; Hurvitz, S A; Mina, L A; Rugo, H S; Lee, K-H; Gonçalves, A; Diab, S; Woodward, N; Goodwin, A; Yerushalmi, R; Roché, H; Im, Y-H; Eiermann, W; Quek, R G W; Usari, T; Lanzalone, S; Czibere, A; Blum, J L; Martin, M; Ettl, J

Crizotinib in ROS1-rearranged advanced non-small-cell lung cancer (NSCLC): updated results, including overall survival, from PROFILE 1001

克唑替尼治疗 ROS1 重排的晚期非小细胞肺癌 (NSCLC):PROFILE 1001 研究的最新结果,包括总生存期

Shaw, A T; Riely, G J; Bang, Y-J; Kim, D-W; Camidge, D R; Solomon, B J; Varella-Garcia, M; Iafrate, A J; Shapiro, G I; Usari, T; Wang, S C; Wilner, K D; Clark, J W; Ou, S-H I

A randomized, double-blind, phase II study of erlotinib with or without sunitinib for the second-line treatment of metastatic non-small-cell lung cancer (NSCLC).

一项随机、双盲、II 期研究,评估厄洛替尼联合或不联合舒尼替尼作为转移性非小细胞肺癌 (NSCLC) 二线治疗的疗效

Groen H J M, Socinski M A, Grossi F, Juhasz E, Gridelli C, Baas P, Butts C A, Chmielowska E, Usari T, Selaru P, Harmon C, Williams J A, Gao F, Tye L, Chao R C, Blumenschein G R Jr